The facts behind Reta
Retatrutide, often called “Reta,” is an investigational triple-agonist weight-loss drug. Early trials look impressive, but the main questions are long-term safety, tolerability, and what happens outside tightly run studies.
Tag
metabolic-health
Metabolic health is where peptide medicines have been most visibly successful. This tag collects evidence-forward posts on obesity, diabetes, and related risk factors.
Start here
LEAP2
Liver-expressed antimicrobial peptide 2 (LEAP2) is an endogenous peptide that antagonizes ghrelin receptor signaling and has been studied in humans for acute effects on appetite and post-meal glucose.
Tirzepatide
A long-acting, synthetic dual agonist of the GLP-1 and GIP receptors, used clinically for type 2 diabetes and obesity.
Glucagon-like peptide-1 (GLP-1)
An endogenous gut hormone peptide that signals through the GLP-1 receptor and forms the biological basis for GLP-1 receptor agonist drugs used in diabetes and obesity.
MOTS-c
A mitochondrial-derived peptide discussed for metabolic resilience and exercise-adjacent effects.
Tesamorelin
An FDA-approved GHRH analog used for HIV-associated lipodystrophy and visceral fat reduction.
When obesity meds get blamed in the OR
A perioperative review argues that adverse effects from modern anti-obesity drugs can be mistaken for surgical or anesthesia complications, raising the bar for documentation, holds, and post-op restarts.
GLP‑1 plus SGLT2 in fatty liver disease
A large real-world analysis links GLP‑1 plus SGLT2 combination therapy to lower rates of major liver and cardiovascular events in people with fatty liver disease and type 2 diabetes.
Rosuvastatin may briefly blunt post-meal GLP‑1
A translational study links cholesterol-pathway inhibition (HMGCR/rosuvastatin) to lower acute GLP‑1 secretion in gut cells and mice, offering a plausible mechanism behind statins’ mild diabetes signal.
MOTS-c levels in teen PCOS look similar
In a small 2026 study of teens, blood levels of the peptide MOTS-c looked broadly similar in polycystic ovary syndrome and controls, and a tested mitochondrial variant was not seen in this group.
AMG 133 and the antibody-peptide obesity strategy
Researchers describe AMG 133, an antibody-peptide conjugate designed to combine GIP receptor antagonism with GLP-1 receptor agonism. It’s a design story about longer-acting multi-target biology, not a new approved therapy.
Which GLP-1 drugs lead on weight loss
A network meta-analysis of phase 3 trials in adults without diabetes found all three major GLP-1 era weight-loss drugs reduced weight vs placebo, with higher-dose tirzepatide ranking highest on average.
An umbrella review asks: do GLP‑1 drugs help heart failure?
A 2026 umbrella review of prior meta-analyses reports GLP‑1 receptor agonists are associated with lower major adverse cardiovascular events and less ‘worsening heart failure’, plus a small improvement in 6‑minute walk distance. Mortality and heart-failure hospitalization results were not clearly improved, and evidence certainty ranged low to moderate.
LEAP2 curbed appetite in men with obesity
In a small randomized crossover study, an intravenous infusion of LEAP2, an endogenous ghrelin receptor antagonist, reduced ad libitum food intake and lowered post-meal glucose in men with obesity.
GLP-1 drugs and thyroid labs: a quiet monitoring gap
A Medicare target-trial emulation found similar thyroid-stimulating hormone (TSH) testing patterns after GLP-1 receptor agonist initiation versus SGLT-2 inhibitors in older adults on stable levothyroxine, despite weight loss often changing thyroid hormone requirements.
A new tirzepatide safety meta-analysis, focused on higher-risk patients
A systematic review and meta-analysis of 21 placebo-controlled trials in patients at increased cardiovascular risk found no clear difference in serious adverse events with tirzepatide, while gastrointestinal side effects remained more common. Mortality evidence was sparse.
When GLP‑1s meet pregnancy planning
A 2026 clinical perspectives paper pulls together what’s known (and unknown) about GLP‑1 drugs and fertility, contraception reliability, and pregnancy planning—plus what the drug labels actually say about washout and birth control.
What people say GLP‑1 side effects feel like (and why Reddit data isn’t the same thing as safety data)
A 2026 medRxiv preprint analyzed 410,198 Reddit posts about semaglutide and tirzepatide. GI symptoms dominated, but the real value is in seeing which experiences people choose to write about—and which clusters might deserve more explicit measurement.
MOTS‑c isn’t a weight-loss switch. It’s a mitochondria signal
MOTS‑c is a real mitochondrial DNA-encoded peptide with intriguing metabolic effects in animal studies, but human evidence is still early and easy to overhype.